Nuvation Bio (NYSE:NUVB) Announces Quarterly Earnings Results

Key Points

• Nuvation Bio missed quarterly EPS estimates, reporting a loss of $0.18 per share versus the expected $0.14 loss, while revenue of $31.69 million exceeded estimates of $27.03 million.
• IBTROZI revenue increased 25% quarter over quarter to $23.2 million, supported by approximately 160 new patient starts and growing first-line adoption. However, management noted that later-line patient additions are slowing, making future growth more dependent on first-line use and improved testing.
• The company expanded safusidenib development and strengthened its balance sheet, ending the quarter with $661 million in liquidity and raising approximately $279 million through convertible notes. Shares traded down 4.4%, while analysts maintained a generally positive outlook with a $12.88 consensus price target.

Nuvation Bio (NYSE:NUVB - Get Free Report) announced its quarterly earnings data on Thursday. The company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.04), FiscalAI reports. The business had revenue of $31.69 million during the quarter, compared to analyst estimates of $27.03 million. Nuvation Bio had a negative net margin of 102.06% and a negative return on equity of 44.10%.

Here are the key takeaways from Nuvation Bio's conference call:

• IBTROZI net revenue rose 25% quarter over quarter to $23.2 million, with approximately 160 new patient starts; 85% were in the first-line setting, up from roughly 30% at launch. Management said IBTROZI is now the ROS1 TKI market leader in first-line and overall new patient starts.
• Management highlighted IBTROZI’s reported 90% response rate and 50-month median duration of response in TKI-naive patients, along with low adverse-event discontinuations and no CNS warning on its label. The company believes these characteristics are driving broad adoption across academic, community, and integrated delivery network accounts.
• Nuvation expanded safusidenib development across all major IDH1-mutant glioma segments, including a new Phase III study in newly diagnosed low-grade disease and a Phase II study in patients whose disease progresses after vorasidenib. In updated J201 data, the response rate increased to 52%, while the 36-month progression-free survival rate was 79%.
• The company ended the quarter with $661 million in cash, cash equivalents, and marketable securities and raised approximately $279 million through low-coupon convertible notes. Management said the financing reduced cash interest expense, strengthened strategic flexibility, and should provide sufficient capital to reach profitability and fund the anticipated safusidenib launch.
• Later-line IBTROZI patient additions are slowing as the company has largely worked through the finite pool of pretreated patients, making future growth increasingly dependent on first-line adoption, improved testing, and converting patients who still receive chemotherapy or immunotherapy.

Nuvation Bio Trading Down 4.4%

NUVB traded down $0.28 during mid-day trading on Thursday, reaching $6.09. The stock had a trading volume of 8,391,554 shares, compared to its average volume of 6,039,828. The firm's fifty day simple moving average is $5.72 and its two-hundred day simple moving average is $5.23. The stock has a market capitalization of $2.12 billion, a P/E ratio of -14.16 and a beta of 1.52. Nuvation Bio has a 52 week low of $2.18 and a 52 week high of $9.75. The company has a debt-to-equity ratio of 0.15, a quick ratio of 7.24 and a current ratio of 7.44.

Insider Transactions at Nuvation Bio

In other Nuvation Bio news, insider Stacy Markel sold 125,000 shares of the business's stock in a transaction dated Tuesday, June 23rd. The stock was sold at an average price of $6.03, for a total transaction of $753,750.00. Following the completion of the sale, the insider directly owned 32,591 shares of the company's stock, valued at approximately $196,523.73. The trade was a 79.32% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kerry Wentworth sold 63,000 shares of the business's stock in a transaction dated Tuesday, June 23rd. The stock was sold at an average price of $6.02, for a total value of $379,260.00. Following the transaction, the insider owned 53,000 shares of the company's stock, valued at $319,060. The trade was a 54.31% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 235,668 shares of company stock valued at $1,419,495 in the last three months. Company insiders own 30.11% of the company's stock.

Institutional Investors Weigh In On Nuvation Bio

Institutional investors have recently added to or reduced their stakes in the stock. Rangeley Capital LLC bought a new stake in Nuvation Bio in the 2nd quarter valued at approximately $25,000. Parallel Advisors LLC increased its stake in Nuvation Bio by 51.9% in the 3rd quarter. Parallel Advisors LLC now owns 7,597 shares of the company's stock valued at $28,000 after buying an additional 2,597 shares during the last quarter. Cetera Investment Advisers bought a new stake in Nuvation Bio during the 2nd quarter worth about $29,000. Captrust Financial Advisors bought a new stake in Nuvation Bio during the 2nd quarter worth about $32,000. Finally, Focus Partners Wealth acquired a new position in shares of Nuvation Bio during the 3rd quarter worth about $49,000. 61.67% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the company. Truist Financial increased their target price on Nuvation Bio from $12.00 to $13.00 and gave the stock a "buy" rating in a report on Tuesday, July 7th. Wedbush reaffirmed an "outperform" rating and issued a $11.00 price target on shares of Nuvation Bio in a research note on Thursday, July 23rd. Weiss Ratings reiterated a "sell (d-)" rating on shares of Nuvation Bio in a research note on Friday, July 17th. Zacks Research raised Nuvation Bio from a "strong sell" rating to a "hold" rating in a report on Monday, July 6th. Finally, Royal Bank Of Canada restated an "outperform" rating on shares of Nuvation Bio in a research note on Wednesday, July 22nd. Eight equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $12.88.

Nuvation Bio Company Profile

Nuvation Bio is a clinical-stage biotechnology company dedicated to discovering and developing small-molecule therapies for patients with cancer. The company employs an integrated research and development platform that spans target identification, preclinical evaluation, process chemistry, and early-stage clinical trials. By centralizing these capabilities, Nuvation Bio aims to accelerate the translation of promising drug candidates from laboratory research to first-in-human studies.

The company's pipeline comprises multiple oncology programs, with small-molecule kinase inhibitors and targeted agents in Phase 1 development for both hematologic malignancies and solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source